One of the two studies already approved will concern multiple sclerosis patients.
Longbrake, E. E. et al. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Some multiple sclerosis patients treat themselves with dozens of stings a day.
Bergamaschi, R. et al. Disability and mortality in a cohort of multiple sclerosis patients: a reappraisal.
Stuve, O. et al. Immune surveillance in multiple sclerosis patients treated with natalizumab.
Multiple sclerosis patients typically lose some problem-solving capacity and short-term memory.
Bar-Or, A. et al. Subcutaneous ofatumumab in relapsing-remitting multiple sclerosis patients: the MIRROR study.
Stüve, O. et al. Immune surveillance in multiple sclerosis patients treated with natalizumab.
Morra, V. B. et al. Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients.
Palanichamy, A. et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.
They said that they completed a safety evaluation of the drug for use in multiple sclerosis patients in August.
